CoreCap Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,086
Closed -$110K 2981
2025
Q4
$110K Buy
1,086
+151
+16% +$12.1K ﹤0.01% 989
2025
Q3
$51.2K Hold
935
﹤0.01% 1318
2025
Q2
$49.7K Buy
935
+890
+1,978% +$45.2K ﹤0.01% 1263
2025
Q1
$1.95K Hold
45
﹤0.01% 2366
2024
Q4
$2.53K Buy
45
+41
+1,025% +$2.55K ﹤0.01% 2164
2024
Q3
$272 Sell
4
-696
-99% -$39.3K ﹤0.01% 2444
2024
Q2
$29.6K Buy
700
+400
+133% +$22K ﹤0.01% 788
2024
Q1
$20.7K Buy
+300
New +$19K ﹤0.01% 1466
2022
Q4
$14.9K Buy
+300
New +$12.3K ﹤0.01% 1407
2022
Q3
Sell
-300
Closed -$12K 1010
2022
Q2
$12K Buy
+300
New +$16K ﹤0.01% 1418
2022
Q1
Sell
-300
Closed -$23K 1016
2021
Q4
$23K Buy
+300
New +$26.5K ﹤0.01% 1282

Other funds holding EXAS

CoreCap Advisors's EXAS Position: Q1 2026 in Review

CoreCap Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 1,086 shares — an estimated $110K sold.

CoreCap Advisors first reported a position in EXAS in Q4 2021 and held it in 11 quarters. The position peaked at $110K in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • CoreCap Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • CoreCap Advisors sold 1,086 Exact Sciences shares in Q1 2026, an estimated $110K.
  • CoreCap Advisors first reported a position in Exact Sciences in Q4 2021 and held it in 11 quarters.
  • CoreCap Advisors's Exact Sciences position peaked at $110K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on CoreCap Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.